| name | Alfuzosin (Uroxatral) |
| classification | Alpha-1 adrenergic antagonist |
| pharmacokinetics | | absorption | Well absorbed after oral administration. Peak plasma concentrations are reached within 2-4 hours. | | distribution | Distributed throughout the body, with significant accumulation in the prostate. | | metabolism | Metabolized primarily in the liver via CYP1A2 and CYP3A4 pathways. | | elimination | Excreted primarily in the urine as metabolites. |
|
| suggested dosage | | initial | 10 mg once daily. | | titration or adjustments | The dose can be increased to a maximum of 10 mg twice daily if needed, depending on the patient's response. It is important to be supervised by a medical professional. | | patient specific considerations | Dosage adjustments might be necessary based on individual patient characteristics and responses, in consultation with a healthcare professional. |
|
| indications | For the symptomatic treatment of benign prostatic hyperplasia (BPH), including urinary obstruction symptoms such as difficulty urinating, weak urine stream, and increased frequency of urination. |
| safety in pregnancy | | category | Category C. | | note | Limited data is available on the use of alfuzosin during pregnancy. It should only be used during pregnancy if the potential benefit outweighs the potential risk to the fetus, under the direct supervision of a physician. Always consult your physician before taking any medication during pregnancy. |
|
| safety in breastfeeding | | note | Alfuzosin is secreted into breast milk, and thus there is some risk. It should be used with caution or not at all during breastfeeding, based on an assessment of risk-benefit by the prescribing physician. |
|
| side effects | | 1 | Headache | | 2 | Dizziness | | 3 | Lightheadedness | | 4 | Fainting | | 5 | Nasal congestion | | 6 | Orthostatic hypotension (low blood pressure upon standing) | | 7 | Abdominal pain | | 8 | Nausea | | 9 | Vomiting | | 10 | Constipation | | 11 | Fatigue | | 12 | Ejaculatory dysfunction | | 13 | Vision changes (rare) |
|
| alternatives | |
| contraindications | | 1 | Hypersensitivity to alfuzosin or other ingredients in the formulation | | 2 | Severe hepatic impairment | | 3 | Severe renal impairment | | 4 | Known history of orthostatic hypotension | | 5 | Concurrent use with certain medications that increase risk of orthostatic hypotension | | 6 | Severe cardiovascular disease, especially angina. |
|
| interactions | | 1 | Certain medications can alter alfuzosin's metabolism or have additive effects on blood pressure. Always inform your healthcare professional about all medications you are taking to avoid any potentially harmful interactions. | | 2 | Examples include: some antihypertensives, nitrates, certain anti-fungals, and more. |
|
| warnings and precautions | | 1 | Patients with pre-existing cardiovascular conditions should use alfuzosin with caution, closely monitoring for orthostatic hypotension. | | 2 | Patients with renal or hepatic impairment may require dosage adjustments. | | 3 | May cause dizziness or lightheadedness; avoid driving or operating machinery until response is evaluated. |
|
| additional informations | | 1 | Important to discuss dosage with physician. Initial low dosage and monitoring of response is required. | | 2 | Monitor blood pressure regularly. | | 3 | Report any unusual symptoms or side effects to your physician. | | 4 | Consult a healthcare professional before taking this medication if you are taking other medications. |
|
| patient specific details | | age | 25 | | weight | 70 | | health status | Assume healthy without other significant conditions. |
|
